Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral capmatinib (INC280) in EGFR wild-type advanced NSCLC
jRCT2080222990Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of capmatinib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Oct 2015; status: completed.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222990.